Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and for chronic inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase II trial for polycythemia vera/essential thrombocythemia; Phase I/II trial to treat other hematologic tumors; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase II clinical trial product for rheumatoid arthritis; INCB28060, a Phase I product for solid cancers; INCB7839, a Phase II product for breast cancer; INCB24360, an IND cleared product for oncology; and INCB13739, a Phase IIb product to treat type 2 diabetes. It has a collaborative research and license agreements with Pfizer Inc.; Novartis International Pharmaceutical Ltd.; and Eli Lilly and Company. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
